MITSUBISHI-ENG-PLASTICS
1.6.2021 03:02:05 CEST | Business Wire | Press release
Mitsubishi Engineering-Plastics Corporation (MEP), a world leader in high-performance polyacetal materials, has developed a new polyacetal resin (POM), the Iupital MA Series, that is compliant with medical standards.
The MA series is available in a range of standard, high-flow, high-rigidity, and low-friction grades, enabling greater design flexibility for medical devices and equipment, which are becoming smaller and lighter.
In particular, the low-friction grade MAL20 has greatly improved sliding performance with POM. In the past, combining POM parts would generate squeaking noise and friction, so designs would combine different materials in order to avoid these issues. MAL20 suppresses friction and wear, even when combined with ordinary POM, achieving quiet, smooth movement, which greatly improves comfort when used in medical devices.
In addition, with the MA series, we will offer a coloring masterbatch for color mixing. We support parts design not only in terms of physical characteristics, but also in terms of visual design.
MEP Vice President, Katsushige Hayashi, said the following. "These new materials, which exhibit a variety of excellent properties, will expand the range of designs, especially for medical devices and instruments, and contribute to improving their functionality. In particular, the sliding grade MAL20 eliminates the discomfort caused by noise and friction due to contact between POMs, providing users with comfort and ease of use."
The Iupital MA series meets the quality and regulatory requirements for medical materials, and is suitable for applications such as drug inhalers for COPD and asthma, injection devices such as insulin pens, and parts for medical devices.
Overview of Mitsubishi Engineering-Plastics Corporation
- Headquarters: Minato-ku, Tokyo
- Branches: Osaka Branch (Osaka, Osaka Prefecture), Nagoya Branch (Nagoya, Aichi Prefecture)
- Technical Base: Technical Center (Hiratsuka, Kanagawa Prefecture)
- President: Takashi Komaya
- Capital: 3 billion yen (50% invested by each of Mitsubishi Gas Chemical Company, Inc. and Mitsubishi Chemical Corporation)
Basic Information on the Iupital ™ MA Series
Features
- We offer a variety of grade groups in addition to the standard grades, including high flow, high rigidity, and low friction
- Masterbatch coloring available
- Worldwide sales and technical support
Grade Lineup
- MAS20 Standard: This is the grade with the most common physical properties and flowability
- MAS30 High flow: This grade has increased flowability. Suitable for precision molding
- MAH25 High rigidity: This grade has increased rigidity and strength. Suitable for making thinner walls and increasing strength
- MAL20 Low-friction: This grade has excellent sliding characteristics. It contributes to low-noise designs with low sliding resistance
Supported Standards, Etc.
- ISO10993-5, 10
- USP [87]
- USP [88] Class IV
- FDA Drug Master File
For data on physical properties, etc., please download it from our website, or contact our sales staff at the nearest head office, branch office, or local subsidiary.
Basic Physical Properties Charts
https://www.m-ep.co.jp/ja/eve/18-2.html (Japanese)
https://www.m-ep.co.jp/en/eve/18-2.html (English)
https://www.m-ep.co.jp/ch/eve/18-2.html (Chinese)
Sales Bases
https://www.m-ep.co.jp/company/kaigai.html (Japanese)
https://www.m-ep.co.jp/en/company/kaigai.html (English)
https://www.m-ep.co.jp/ch/company/kaigai.html (Chinese)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210531005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom